Evidence map›Paper›PMID 33669204›Full record

ReviewInternational journal of molecular sciences2021

The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.

Mai-Huong Thi Ngo, Han-Yin Jeng, Yung-Che Kuo, Josephine Diony Nanda, Ageng Brahmadhi, Thai-Yen Ling, Te-Sheng Chang, Yen-Hua Huang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Liver-specific actions of GH and IGF1 that protect against MASLD.Nature reviews. Endocrinology · 2025 · on this map
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mai-Huong Thi NgoInternational PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Han-Yin JengResearch Center of Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-1867-2177
Yung-Che KuoResearch Center of Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Josephine Diony NandaInternational PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Ageng BrahmadhiInternational PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Thai-Yen LingDepartment and Graduate Institute of Pharmacology, National Taiwan University, Taipei 11031, Taiwan.
Te-Sheng ChangSchool of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33382, Taiwan.ORCID 0000-0002-1581-6948
Yen-Hua HuangInternational PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-6020-9998
Taipei Medical University · TWChang Gung University · TWNational Taiwan University · TWTaipei Medical University Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST105-2628-B-038-008-MY3Ministry of Science and Technology, Taiwan MOST106-3114-B-038-001Ministry of Science and Technology, Taiwan MOST107-2314-B-038-057Ministry of Science and Technology, Taiwan MOST107-2314-B-038-061Ministry of Science and Technology, Taiwan MOST107-2321-B-038-002Ministry of Science and Technology, Taiwan MOST108-2314-B-038-006Ministry of Science and Technology, Taiwan MOST108-2321-B-038-003Ministry of Science and Technology, Taiwan MOST 109-2314-B-038-135Ministry of Science and Technology, Taiwan MOST 109-2321-B-038-003
6 · The paper itself

Abstract

Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.

Indexed as

Signal TransductionCarcinoma, HepatocellularCytokinesDrug Resistance, NeoplasmHepatitis BHepatitis B virusHumansLiver NeoplasmsMolecular Targeted TherapyNeoplasm Recurrence, LocalProtein Kinase InhibitorsReceptor, IGF Type 1SomatomedinsVirus ReplicationCytokinesIGF1R protein, humanProtein Kinase InhibitorsReceptor, IGF Type 1Somatomedinscancer stemnessIGFs inhibitorinsulin-like growth factorliver cancertargeting drug resistance

Identifiers

PMID33669204
PMCPMC7919800
OpenAlexW3131916754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.